Biocytogen, a biomedical contract research organization (CRO) specialized in gene-targeted animal models and services, announced on Thursday that it has raised RMB543 million (US$77.11 million) in a series D round of financing.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access Over 11,000 stories and data posts over the past 8 years!Register Now
Already have an account or paid subscription?